|Day Low/High||7.00 / 7.16|
|52 Wk Low/High||6.64 / 11.74|
Trade-Ideas LLC identified MiMedx Group (MDXG) as a weak on high relative volume candidate
New Lyophilized OrthoFlo version is an advancement in product logistics and safety
$57.3 MILLION Q2 2016 REVENUE IS 26% INCREASE OVER Q2 2015
In trading on Friday, shares of MiMedx Group Inc crossed above their 200 day moving average of $8.34, changing hands as high as $8.38 per share. MiMedx Group Inc shares are currently trading up about 2.7% on the day.
Case series determines wounds with exposed bone or tendon treated with dHACM and STSG is viable low-cost treatment alternative to the gold standard for limb salvage
The wound care provider filed the suit for allegedly falsifying and misleading consumers with clinical data.
Company Reiterates Second Quarter Guidance
Trade-Ideas LLC identified MiMedx Group (MDXG) as a strong on high relative volume candidate
The most recent short interest data was recently released for the 03/31/2016 settlement date, and MiMedx Group Inc is one of the most shorted stocks of the Russell 3000, based on 19.83 "days to cover" versus the median component at 6.16. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Review is flawed with unmatched, uncontrolled and subjective variables
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, ALSN, BANR, CPHR, FARM, FBP, FOX, FOXA, HDS, HL, KMDA, MSM, PBA, QUOT, SAMG, SCHN, XNCR Downgrades: AGNC, EJ, MDXG, XRX, ZHNE Initiations: COYN Read on to get TheStreet Quant Ratings' detailed report:
Poster Abstracts Demonstrate Clinical and Cost Effective Results of EpiFix Allografts in healing diabetic foot ulcers, chronic diabetic lower extremity ulcerated wounds, venous leg ulcers, refractory non-healing wounds, and hard to treat wounds
MiMedx (MDXG) stock is tumbling on Monday afternoon following the early release of the company's 2016 first quarter revenue results yesterday.
$53.4 MILLION Q1 2016 REVENUE IS 31% INCREASE OVER Q1 2015
In trading on Thursday, shares of MiMedx Group Inc crossed above their 200 day moving average of $9.29, changing hands as high as $9.30 per share. MiMedx Group Inc shares are currently trading up about 0.7% on the day.